Prevention and Treatment of Tumor Lysis Syndrome in the Era of Onco-Nephrology Progress
Background: Tumor lysis syndrome (TLS) is an oncologic emergency due to a rapid break down of malignant cells usually induced by cytotoxic therapy, with hyperuricemia, hyperkalemia, hyperphosphatemia, hypocalcemia, and serious clinical consequences such as acute renal injury, cardiac arrhythmia, hyp...
Main Authors: | Joanna Matuszkiewicz-Rowinska, Jolanta Malyszko |
---|---|
Format: | Article |
Language: | English |
Published: |
Karger Publishers
2020-09-01
|
Series: | Kidney & Blood Pressure Research |
Subjects: | |
Online Access: | https://www.karger.com/Article/FullText/509934 |
Similar Items
-
Prevention and treatment of tumor lysis syndrome, and the efficacy and role of rasburicase
by: Alakel N, et al.
Published: (2017-02-01) -
Efficacy of single-dose rasburicase in the management of tumor lysis syndrome: a case series from a regional cancer center in western India
by: Sandeep R Kukkar, et al.
Published: (2016-01-01) -
Update on tumor lysis syndrome management
by: P Angsuwatcharakon, et al.
Published: (2006-08-01) -
A rare case of spontaneous tumor lysis syndrome in multiple myeloma
by: Louay Aldabain, et al.
Published: (2020-07-01) -
Influence of hyperuricemia treatment on postoperative acute kidney injury among hyperuricemia patients: a single-center retrospective database analysis
by: Shinichiro Watanabe, et al.
Published: (2019-11-01)